Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
Christopher W. Ryan(Oregon Health & Science University), E. David Crawford(University of California San Diego)
Cited by 152
Related Papers
Multiple loci identified in a genome-wide association study of prostate cancer
|Nature Genetics|2008|907
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
|The Lancet|2019|472